Korean J Gastroenterol.  2002 Sep;40(3):214-217.

A Case of Ticlopidine-induced Cholestatic Hepatitis Which Showed a Prompt Response to Steroid

Affiliations
  • 1Department of Internal Medicine, Seoul Paik Hospital, Seoul, Korea. ghwoo@korea.com
  • 2Department of Pathology, Seoul Paik Hospital, Seoul, Korea.
  • 3Department of Internal Medicine, Ilsan Paik Hospital, Inje University College of Medicine, Seoul, Korea.

Abstract

Ticlopidine hydrochloride is a platelet aggregation inhibitor used for the prevention of thromboembolic disease in patients at high risk of stroke, or for the prevention of thrombosis after coronary artery stent. Hepatotoxicity was reported in 0-4.4% of the patients receiving ticlopidine therapy, consisting mainly of asymptomatic elevation of alkaline phosphatase. Hepatic toxicity is mainly characterized by cholestasis with cytotoxic injury. The pathogenesis of hepatotoxicity is unknown, but some suggested that the hepatic injury occurs as a result of hypersensitivity to the drug. Ticlopidine-induced hepatitis is usually improved after cessation of the drug, but in some cases, it is prolonged. The treatment of prolonged ticlopidine-induced hepatitis has not yet been established. We report a case of ticlopidine-induced cholestatic hepatitis, in which jaundice and the result of liver function test was progressively worsened until 25 days after discontinuation of the drug. However, it responded promptly to steroid administration.

Keyword

Hepatitis; Cholestasis; intrahepatic; Ticlopidine; Steroids

MeSH Terms

Alkaline Phosphatase
Cholestasis
Coronary Vessels
Hepatitis*
Humans
Hypersensitivity
Jaundice
Liver Function Tests
Platelet Aggregation
Stents
Steroids
Stroke
Thrombosis
Ticlopidine
Alkaline Phosphatase
Steroids
Ticlopidine
Full Text Links
  • KJG
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr